Hemato Oncology Testing Market - Top Companies and Manufacturers

  • Report ID: 6632
  • Published Date: Nov 04, 2024
  • Report Format: PDF, PPT

Companies Dominating the Hemato Oncology Testing Landscape

    The key players in the hemato oncology testing market are employing several organic and inorganic tactics to earn high profits and increase their market reach. Leading companies are collaborating with other players and research organizations to develop innovative hemato oncology testing technologies. Such strategic partnerships are also aiding them to improve their product offerings.  Furthermore, market players are entering into mergers & acquisitions and regional expansion strategies to reach a wider audience base. 

    Some of the key players include:

    • F. Hoffmann-La Roche AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Abbott Laboratories
    • ARUP Laboratories
    • Bio-Rad Laboratories Inc.
    • Danaher Corporation
    • Entrogen Inc.
    • Illumina, Inc.
    • Invivoscribe, Inc.
    • Invitae Corporation
    • Qiagen N.V.
    • Thermo Fisher Scientific, Inc.
    • Vela Diagnostics
    • Horiba Medical

Browse Key Market Insights with Data Illustration:

In the News

  • In September 2024, F. Hoffmann-La Roche AG announced the expansion of its digital diagnostic offerings. Its digital pathology environment was integrated with over 20 new advanced AI algorithms from 8 new collaborators. This move is expected to boost the company’s AI-enabled cancer diagnostics division.
  • In April 2024, Horiba Medical announced the launch of its next-gen fully automated modular hematology solution. This CE-IVDR-approved solution offers flexible and high-quality analytical performance.
  • In November 2023, Roswell Park Comprehensive Cancer Center announced the development of innovative, high-speed blood cancer tests. The PanHeme test is based on next-gen gene sequencing technology that effectively detects hemato oncology such as leukemia, lymphoma, and myeloma.

Author Credits:  Radhika Pawar


  • Report ID: 6632
  • Published Date: Nov 04, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The global hemato oncology testing market will be valued at 4.1 billion in 2025.

Expanding at a CAGR of 14.5%, the global market is expected to increase from USD 3.6 billion in 2024 to USD 20.8 billion by 2037.

Some leading companies are F. Hoffmann-La Roche AG, Abbott Laboratories, ARUP Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, Entrogen Inc., and Illumina, Inc.

The kits & reagents segment is estimated to capture a strong 41.3% of the market share through 2037.

North America region is expected to hold 44.3% of the global market share through 2037.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample